Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

University of California, Los Angeles (UCLA)

Status: Enrolling

Conditions: Glaucoma; Ocular Surface Disease

Treatments: Drug: Xiidra (Lifitegrast ophthalmic solution) 5%

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04354545

19-000843

Details and patient eligibility

About

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Full description

To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma antihypertensive medications.

Enrollment: 75 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Currently using one or more topical glaucoma antihypertensives
• Self-described symptoms of ocular surface discomfort
• Xiidra is being prescribed as part of the subject's standard care

Exclusion criteria

• History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
• current use of topical cyclosporine
• current use of topical steroids
• incisional ocular surgery within 6 months

Trial design

75 participants in 1 patient group

Group 1

Description:

Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks

Treatment:

Drug: Xiidra (Lifitegrast ophthalmic solution) 5%